Facebook
Twitter
LinkedIn
Forward
“Let’s Talk About It!” - Biology and Management of Sexual Toxicity Resulting from Prostate Cancer Radiotherapy
Radiation therapy-induced erectile dysfunction (RI-ED) occurs in over 50% of men treated for prostate cancer. The etiologies are likely multifactorial, consisting of a neurological, vascular and endocrine component. Since RI-ED significantly impacts quality of life and therefore may influence a patient’s decision to pursue radiation treatment, understanding the pathophysiology, preventative measures, and treatment options are important for both the patient and the health care provider. Specific guidelines for RI-ED prevention and rehabilitation in prostate cancer patients have been lacking. However, with the evolution of CT- and MR-guided radiotherapy, novel brachytherapy techniques, and drugs to alter erectile hemodynamics, attempts are being made to mitigate the sexual toxicities of radiotherapy and androgen deprivation therapy.
Topics:
- Pathogenesis and Pre-Clinical Models of Sexual Toxicities Arising from Prostate Cancer Radiation Therapy
Susan M. LaRue, DVM, PhD, ACVS, ACVR(RO) - Sexual Function Preservation
William McLaughlin, MD - Evaluation and Management of Radiation Therapy- and Androgen Deprivation Therapy-Induced Sexual Dysfunction: Psychosocial, Lifestyle, Medical, and Surgical Options
John Patrick Mulhall, MD - Testosterone Replacement Therapy (TRT) Following Radiation Treatment for Prostate Cancer: Are We Doing a Disservice or Providing a Benefit?
Andrew W. Pastuszak, MD, PhD - Q and A
Craig E. Grossman, MD, PhD, MS - Moderator
Full Panel
This activity is available from June 10, 2025, through 11:59 p.m. Eastern time on June 9, 2027.
The content was originally presented and recorded at the 2024 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, radiation therapists, dosimetrists, radiation biologists, residents, urologists, sexual therapists, mental health professionals and social workers. .
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify the causes of sexual dysfunction resulting from radiation and androgen deprivation therapy and consider approaches to mitigate such toxicity.
- Evaluate, prevent and manage radiotherapy- and androgen deprivation therapy-induced sexual dysfunction.
- Discuss the impact of testosterone replacement therapy (TRT) on oncologic outcomes with their hypogonadal patients who were previously treated for prostate cancer.
- Craig E. Grossman, MD, PhD, MS, is employed by University of South Florida Morsani College of Medicine and Tampa General Hospital.
- Susan M. LaRue, DVM, PhD, ACVS, ACVR(RO), is employed by Colorado State University.
- William McLaughlin, MD, is employed by University of Michigan.
- John Patrick Mulhall, MD, is employed by Memorial Sloan Kettering Cancer Center. Dr. Mulhall owns stock in Ro and Firm Tech. Dr. Mulhall serves as Editor-in-Chief of the Journal of Sexual Medicine and is a non-voting member on the Board of Directors of the Sexual Medicine Society of North America (SMSNA).
- Alexander W. Pastuszak, MD, PhD, is employed by University of Utah School of Medicine. Dr. Pastuszak receives compensation/payment from Contraline. Dr. Pastuszak receives compensation as the CEO of Paterna Biosciences. Dr. Pastuszak serves as a consultant/advisor for Alto Neurosciences, Macro Trials, Inherent Biosciences and Endo Pharmaceuticals.
The person(s) above served as the developer(s) of this activity. Additionally, the ASTRO Education Committee had control over the content of this activity. All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.25 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
- Nonmember: $149
- Member: $99
- Member-in-Training: $49
- Student/Graduate Student/PGY-1 Member: $49
- Postdoctoral Fellow Member: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until June 9, 2027, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.